AU2002247939B2 - Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists - Google Patents

Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists Download PDF

Info

Publication number
AU2002247939B2
AU2002247939B2 AU2002247939A AU2002247939A AU2002247939B2 AU 2002247939 B2 AU2002247939 B2 AU 2002247939B2 AU 2002247939 A AU2002247939 A AU 2002247939A AU 2002247939 A AU2002247939 A AU 2002247939A AU 2002247939 B2 AU2002247939 B2 AU 2002247939B2
Authority
AU
Australia
Prior art keywords
dao
polypeptide
seq
ddo
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002247939A
Other languages
English (en)
Other versions
AU2002247939B9 (en
AU2002247939A1 (en
Inventor
Ilya Chumakov
Daniel Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Serono Genetics Institute SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Genetics Institute SA filed Critical Serono Genetics Institute SA
Publication of AU2002247939B9 publication Critical patent/AU2002247939B9/en
Publication of AU2002247939A1 publication Critical patent/AU2002247939A1/en
Assigned to GENSET S.A. reassignment GENSET S.A. Amend patent request/document other than specification (104) Assignors: GENSET
Assigned to SERONO GENETICS INSTITUTE S.A. reassignment SERONO GENETICS INSTITUTE S.A. Amend patent request/document other than specification (104) Assignors: GENSET S.A.
Application granted granted Critical
Publication of AU2002247939B2 publication Critical patent/AU2002247939B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
AU2002247939A 2001-01-16 2002-01-15 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists Ceased AU2002247939B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US26188301P 2001-01-16 2001-01-16
US60/261,883 2001-01-16
US30544501P 2001-07-13 2001-07-13
US60/305,445 2001-07-13
US34521101P 2001-10-22 2001-10-22
US60/345,211 2001-10-22
US33388101P 2001-11-19 2001-11-19
US60/333,881 2001-11-19
PCT/IB2002/001262 WO2002066672A2 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Publications (3)

Publication Number Publication Date
AU2002247939B9 AU2002247939B9 (en) 2002-09-04
AU2002247939A1 AU2002247939A1 (en) 2003-02-27
AU2002247939B2 true AU2002247939B2 (en) 2007-01-25

Family

ID=27500728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002247939A Ceased AU2002247939B2 (en) 2001-01-16 2002-01-15 Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists

Country Status (11)

Country Link
EP (1) EP1412515A2 (https=)
JP (1) JP2004537275A (https=)
KR (1) KR20030066813A (https=)
CN (1) CN1568370A (https=)
AU (1) AU2002247939B2 (https=)
BR (1) BR0206495A (https=)
CA (1) CA2433866A1 (https=)
EA (1) EA006654B1 (https=)
IL (1) IL156865A0 (https=)
MX (1) MXPA03006321A (https=)
WO (1) WO2002066672A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60228954D1 (en) 2001-05-03 2008-10-30 Galileo Lab Inc Pyruvatderivate
WO2003070743A1 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20060234221A1 (en) * 2001-12-12 2006-10-19 Genset S.A. Biallelic markers of d-amino acid oxidase and uses thereof
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
JP2007517056A (ja) 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールｄａａｏ阻害剤
JP5367377B2 (ja) * 2006-01-09 2013-12-11 オクラホマ メディカル リサーチ ファウンデーション 炎症性疾患治療のためのランチオニン関連化合物
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
GB2456390A (en) * 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
CN102292094B (zh) 2009-01-20 2013-08-14 洛杉矶生物医学研究所在哈伯-加州大学洛杉矶分校医疗中心 增强神经药方疗效的山梨酸与苯甲酸及其衍生物
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
WO2012135119A1 (en) * 2011-03-25 2012-10-04 Genomind, Llc Biomarker-based detection and treatment of neurodegenerative depression
AU2013203395A1 (en) 2012-03-30 2013-10-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
ES2936094T3 (es) 2016-06-13 2023-03-14 Syneurx Int Taiwan Corp Cocristales de benzoato de sodio y usos de los mismos
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN108504752B (zh) * 2018-06-26 2021-05-11 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN111909907B (zh) * 2020-07-08 2022-05-24 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP1165836A2 (en) * 1999-03-30 2002-01-02 Genset Schizophrenia associated genes, proteins and biallelic markers
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
AU2002247939B9 (en) 2002-09-04
JP2004537275A (ja) 2004-12-16
EA200300807A1 (ru) 2004-08-26
CN1568370A (zh) 2005-01-19
EP1412515A2 (en) 2004-04-28
BR0206495A (pt) 2006-01-24
WO2002066672A2 (en) 2002-08-29
IL156865A0 (en) 2004-02-08
WO2002066672A3 (en) 2004-02-26
KR20030066813A (ko) 2003-08-09
MXPA03006321A (es) 2003-10-06
CA2433866A1 (en) 2002-08-29
EA006654B1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
AU2002247939B9 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
AU2002247939A1 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2003047558A2 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
Wang et al. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions
JP4018884B2 (ja) 脊柱筋萎縮症の治療
Gainetdinov et al. Functional hyperdopaminergia in dopamine transporter knock-out mice
US8546090B2 (en) SIRT4 activities
CA2257857A1 (en) Screening methods for compounds useful in the regulation of body weight
US20030185754A1 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2014179303A1 (en) Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
MX2007015225A (es) Chaperonas farmacologicas para el tratamiento de obesidad.
Tarazi et al. Brain dopamine D4 receptors: basic and clinical status
Patel et al. Role of transporters and enzymes in metabolism and distribution of 4-chlorokynurenine (AV-101)
Reed et al. Discovery of VU6027459: a first-in-class selective and CNS penetrant mGlu7 positive allosteric modulator tool compound
CN101896815A (zh) 肠疾病中的新的治疗靶标
US20030166554A1 (en) Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
JP2005525112A (ja) ジアシルグリセロールキナーゼεを使用して疼痛を処置する際の方法および組成物
EP0915706A1 (en) Screening methods for compounds useful in the regulation of body weight
Naranjo et al. Neurodevelopmental liabilities in alcohol dependence: central serotonin and dopamine dysfunction
Sourkes Biochemistry of mental depression
JP2005514940A (ja) １４３５分子、５５９分子、３４０２１分子、４４０９９分子、２５２７８分子、６４１分子、２６０分子、５５０８９分子、２１４０７分子、４２０３２分子、４６６５６分子、６２５５３分子、３０２分子、３２３分子、１２３０３分子、９８５分子、１３２３７分子、１３６０１分子、１８９２６分子、３１８分子、２０５８分子または６３５１分子を用いる泌尿器疾患を処置するための方法および組成物
JP2005518346A (ja) ドパミン作動性ニューロンの調節
Tsuji et al. Neu1 sialidase regulates heterospecific social interaction in zebrafish via D1 dopamine receptor
Finsterer Familiar amyotrophic lateral sclerosis
Bahremand Potentiel thérapeutique de JJ-3-42, un nouvel agoniste sélectif des récepteurs 5-HT2C, dans le traitement des maladies psychiatriques

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT/PATENTEE FROM GENSET TO GENSET S.A.

TC Change of applicant's name (sec. 104)

Owner name: SERONO GENETICS INSTITUTE S.A.

Free format text: FORMER NAME: GENSET S.A.

FGA Letters patent sealed or granted (standard patent)
SREP Specification republished
MK14 Patent ceased section 143(a) (annual fees not paid) or expired